LAUSR

Cardiac disorder-related adverse events for aryl hydrocarbon receptor agonists: a safety review

Sign Up to like & get
recommendations!
1 Published in 2022 at "Expert Opinion on Drug Safety"

DOI: 10.1080/14740338.2022.2078301

Abstract: ABSTRACT Background Although cardiac disorder-related adverse events (AEs) have been reported in patients treated with aryl hydrocarbon receptor (AHR) agonists, their safety profiles remain unknown. Here, we identified significant cardiac disorders associated with AHR agonists… read more here.

Keywords: safety; disorder related; cardiac disorder; related adverse ... See more keywords